Lead as an environmental toxicant in models of synucleinopathies
- PMID: 40347673
- DOI: 10.1016/j.chemosphere.2025.144477
Lead as an environmental toxicant in models of synucleinopathies
Abstract
Lead, a toxic heavy metal, is prevalent in various industrial applications, contributing to environmental contamination and significant health concerns. Lead affects various body systems, especially the brain, causing long-lasting cognitive and behavioral changes. While most studies have focused on continuous lead exposure, intermittent exposure, such as that caused by migration or relocations, has received less attention. Importantly, lead exposure intensifies the severity of Parkinson's disease (PD) and dementia with Lewy bodies, diseases involving the accumulation of alpha-synuclein (aSyn) in the brain and in the gut. Although the precise mechanisms underlying these observations remain unclear, oxidative stress and mitochondrial dysfunction likely play a role. Here, we investigated how two different profiles of lead exposure - continuous and intermittent - affect models of synucleinopathies. We found that lead exposure enhances the formation of aSyn inclusions, resulting in an increase in both their number and size in cell models. In addition, we found that animals injected with aSyn pre-formed fibrils display serine 129-phosphorylated aSyn inclusions and a reduction in astrocytes in the substantia nigra. These animals also display neuronal damage and alterations in locomotor activity, exploration behavior, anxiety, memory impairments and hypertension. Our results suggest a mechanistic link between environmental lead exposure and the onset and progression of diseases associated with aSyn pathology. Understanding the molecular and cellular interactions between lead and aSyn is crucial for shaping public health policies and may provide novel insight into strategies for mitigating the impact of environmental toxins on neurodegenerative processes involved in Parkinson's disease and related synucleinopathies.
Keywords: Alpha-synuclein; Environmental factor; Heavy-metal exposure; Lead; Parkinson's disease; Synucleinopathies.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Liana Shvachiy reports financial support was provided by Foundation for Science and Technology. Tiago F. Outeiro reports financial support was provided by German Research Foundation. Vera Geraldes reports financial support was provided by Foundation for Science and Technology, Lisbon, Portugal. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges.Int J Mol Sci. 2025 Jun 4;26(11):5405. doi: 10.3390/ijms26115405. Int J Mol Sci. 2025. PMID: 40508212 Free PMC article. Review.
-
Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.Neurobiol Dis. 2020 Jul;141:104876. doi: 10.1016/j.nbd.2020.104876. Epub 2020 Apr 25. Neurobiol Dis. 2020. PMID: 32339655 Review.
-
Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles.Elife. 2024 Nov 25;13:RP92775. doi: 10.7554/eLife.92775. Elife. 2024. PMID: 39584804 Free PMC article.
-
Protein trapping leads to altered synaptic proteostasis in synucleinopathies.FEBS J. 2020 Dec;287(24):5294-5303. doi: 10.1111/febs.15364. Epub 2020 May 23. FEBS J. 2020. PMID: 32400966
-
Mechanisms of alpha-synuclein toxicity: An update and outlook.Prog Brain Res. 2020;252:91-129. doi: 10.1016/bs.pbr.2019.10.005. Epub 2019 Nov 23. Prog Brain Res. 2020. PMID: 32247376 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources